GlassScriptPhysician profile
Maya M Shah
NPI 1285734301
$1,781.73
in general payments reported to CMS, 2019-2025
32 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $327 · 2021: $372 · 2022: $145 · 2023: $274 · 2024: $209 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.92 |
| Education | $116.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $274.50 | 2019-2025 | Keytruda |
| Incyte Corporation | $210.19 | 2019-2023 | Jakafi |
| Janssen Biotech, INC. | $127.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $125.92 | 2019-2023 | Lynparza |
| Seagen INC. | $121.08 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $101.91 | 2019-2023 | Opdivo |
| Glaxosmithkline, LLC. | $97.89 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Daiichi Sankyo INC. | $94.80 | 2021-2025 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $92.28 | 2019-2020 | |
| Amgen INC. | $63.38 | 2019-2022 | |
| Genzyme Corporation | $49.95 | 2020-2023 | |
| Puma Biotechnology, INC. | $46.15 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.66 | 2019 | |
| Celgene Corporation | $30.85 | 2020-2022 | |
| Csl Behring | $24.85 | 2023 | Hemgenix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $21.61 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.52 | 2023 | |
| Tactile Systems Technology INC | $20.16 | 2025 | Flexitouch Plus, Nimbl |
| Stemline Therapeutics INC. | $19.55 | 2022 | |
| Exelixis INC. | $19.05 | 2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $16.80 | 2021 | |
| Pfizer INC. | $15.50 | 2024 | |
| Astellas Pharma US INC | $15.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.96 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.92 | 2019 | |
| Emd Serono, INC. | $14.70 | 2024 | |
| Abbvie INC. | $14.56 | 2019 | |
| Blueprint Medicines Corporation | $14.10 | 2020 | |
| Eisai INC. | $13.64 | 2022 | |
| Servier Pharmaceuticals LLC | $12.72 | 2020 | |
| Tesaro, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.